Wu S - Search Results

1

Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Kollmannsberger C, Bjarnason G, Burnett P, Creel P, Davis M, Dawson N, Feldman D, George S, Hershman J, Lechner T, Potter A, Raymond E, Treister N, Wood L, Wu S, Bukowski R. Kollmannsberger C, et al. Among authors: wu s. Oncologist. 2011;16(5):543-53. doi: 10.1634/theoncologist.2010-0263. Epub 2011 Apr 13. Oncologist. 2011. PMID: 21490127 Free PMC article. Review.

2

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Lacouture ME, et al. Among authors: wu s. Oncologist. 2008 Sep;13(9):1001-11. doi: 10.1634/theoncologist.2008-0131. Epub 2008 Sep 8. Oncologist. 2008. PMID: 18779536 Free article. Review.

3

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. Balagula Y, et al. Among authors: wu s. Invest New Drugs. 2012 Aug;30(4):1773-81. doi: 10.1007/s10637-011-9652-2. Epub 2011 Mar 11. Invest New Drugs. 2012. PMID: 21394443 Review.

4

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.

Chu D, Lacouture ME, Weiner E, Wu S. Chu D, et al. Among authors: wu s. Clin Genitourin Cancer. 2009 Jan;7(1):11-9. doi: 10.3816/CGC.2009.n.002. Clin Genitourin Cancer. 2009. PMID: 19213662

5

Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.

Zarrabi K, Wu S. Zarrabi K, et al. Among authors: wu s. Curr Oncol Rep. 2018 Apr 2;20(5):41. doi: 10.1007/s11912-018-0684-z. Curr Oncol Rep. 2018. PMID: 29611002 Review.

6

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.

Zhu X, Stergiopoulos K, Wu S. Zhu X, et al. Among authors: wu s. Acta Oncol. 2009;48(1):9-17. doi: 10.1080/02841860802314720. Acta Oncol. 2009. PMID: 18752081 Review.

7

Alopecia with endocrine therapies in patients with cancer.

Saggar V, Wu S, Dickler MN, Lacouture ME. Saggar V, et al. Among authors: wu s. Oncologist. 2013;18(10):1126-34. doi: 10.1634/theoncologist.2013-0193. Epub 2013 Sep 13. Oncologist. 2013. PMID: 24037977 Free PMC article.

8

An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.

Zarrabi K, Wu S. Zarrabi K, et al. Among authors: wu s. Expert Opin Biol Ther. 2018 Jun;18(6):695-705. doi: 10.1080/14712598.2018.1478962. Epub 2018 Jun 4. Expert Opin Biol Ther. 2018. PMID: 29782188 Review.

9

New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.

Zarrabi K, Fang C, Wu S. Zarrabi K, et al. Among authors: wu s. J Hematol Oncol. 2017 Feb 2;10(1):38. doi: 10.1186/s13045-016-0374-y. J Hematol Oncol. 2017. PMID: 28153029 Free PMC article. Review.

10

Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.

Jia Y, Lacouture ME, Su X, Wu S. Jia Y, et al. Among authors: wu s. J Support Oncol. 2009 Nov-Dec;7(6):211-7. J Support Oncol. 2009. PMID: 20380328

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39,771 results

Search Page

Filters